All Outputs (44)

Real‐world persistence of multiple sclerosis disease‐modifying therapies (2024)
Journal Article

Background and purpose: Treatment persistence is the continuation of therapy over time. It reflects a combination of treatment efficacy and tolerability. We aimed to describe real‐world rates of persistence on disease‐modifying therapies (DMTs) for p... Read More about Real‐world persistence of multiple sclerosis disease‐modifying therapies.

The Impact of COVID-19 on the Employment of People With Multiple Sclerosis: A Multi-Methods Study (2024)
Journal Article

Background: The COVID-19 pandemic led to approximately half of the working population in the United Kingdom being unable to work temporarily. This study aims to understand the employment needs and experiences of people with multiple sclerosis (MS) in... Read More about The Impact of COVID-19 on the Employment of People With Multiple Sclerosis: A Multi-Methods Study.

Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination (2023)
Journal Article

Background: People with multiple sclerosis (pwMS) treated with certain disease-modifying therapies (DMTs) have attenuated IgG response following COVID-19 vaccination; however, the clinical consequences remain unclear. Objective: To report CO... Read More about Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination.

Real-world annualized relapse rates from contemporary multiple sclerosis clinics in the UK: a retrospective multicentre cohort study (2023)
Journal Article

Background: Annualized relapse rate (ARR) is used as an outcome measure in multiple sclerosis (MS) clinical trials. Previous studies demonstrated that ARR has reduced in placebo groups between 1990 and 2012. This study aimed to estimate real-world AR... Read More about Real-world annualized relapse rates from contemporary multiple sclerosis clinics in the UK: a retrospective multicentre cohort study.

ADAMS project: a genetic Association study in individuals from Diverse Ancestral backgrounds with Multiple Sclerosis based in the UK. (2023)
Journal Article

Purpose Genetic studies of multiple sclerosis (MS) susceptibility and severity have focused on populations of European ancestry. Studying MS genetics in other ancestral groups is necessary to determine the generalisability of these findings. The gene... Read More about ADAMS project: a genetic Association study in individuals from Diverse Ancestral backgrounds with Multiple Sclerosis based in the UK..

An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis (2023)
Journal Article

Multiple sclerosis (MS) is an immune-mediated disorder of the CNS manifested by recurrent attacks of neurological symptoms (related to focal inflammation) and gradual disability accrual (related to progressive neurodegeneration and neuroinflammation)... Read More about An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis.

Developing a Patient Care Pathway for Emotional Support around the point of Multiple Sclerosis diagnosis: A Stakeholder Engagement Study (2023)
Journal Article

Background: Diagnosing multiple sclerosis (MS) can be a lengthy process, which can impact psychological wellbeing, condition management, and future engagement with health services. Therefore, providing timely and appropriate emotional support may imp... Read More about Developing a Patient Care Pathway for Emotional Support around the point of Multiple Sclerosis diagnosis: A Stakeholder Engagement Study.

Paramagnetic rims are a promising diagnostic imaging biomarker in multiple sclerosis (2022)
Journal Article

Background: White matter lesions (WMLs) on brain magnetic resonance imaging (MRI) in multiple sclerosis (MS) may contribute to misdiagnosis. In chronic active lesions, peripheral iron-laden macrophages appear as paramagnetic rim lesions (PRLs). Objec... Read More about Paramagnetic rims are a promising diagnostic imaging biomarker in multiple sclerosis.

Longitudinal clinical study of patients with iron rim lesions in multiple sclerosis (2022)
Journal Article

Background: Iron rims (IRs) surrounding white matter lesions (WMLs) are suggested to predict a more severe disease course. Only small longitudinal cohorts of patients with and without iron rim lesions (IRLs) have been reported so far. Objective: To a... Read More about Longitudinal clinical study of patients with iron rim lesions in multiple sclerosis.

Decentralised clinical trials in multiple sclerosis research (2022)
Journal Article

Randomised controlled trials (RCTs) play an important role in multiple sclerosis (MS) research, ensuring that new interventions are safe and efficacious before their introduction into clinical practice. Trials have been evolving to improve the robust... Read More about Decentralised clinical trials in multiple sclerosis research.

Neuropsychological evaluation and rehabilitation in multiple sclerosis (NEuRoMS): protocol for a mixed-methods, multicentre feasibility randomised controlled trial (2022)
Journal Article

Background: Cognitive problems affect up to 70% of people with multiple sclerosis (MS), which can negatively impact mood, ability to work, and quality of life. Addressing cognitive problems is a top 10 research priority for people with MS. Our ongoin... Read More about Neuropsychological evaluation and rehabilitation in multiple sclerosis (NEuRoMS): protocol for a mixed-methods, multicentre feasibility randomised controlled trial.

Effectiveness of acceptance and commitment therapy for improving quality of life and mood in individuals with multiple sclerosis: A systematic review and meta-analysis (2022)
Journal Article

Objective: To review the evidence for the effectiveness of Acceptance and Commitment Therapy (ACT) intervention on quality of life and mood, for individuals with Multiple Sclerosis (MS). Method: A systematic search was conducted of PsycINFO, CINAHL,... Read More about Effectiveness of acceptance and commitment therapy for improving quality of life and mood in individuals with multiple sclerosis: A systematic review and meta-analysis.

Experiences of receiving a diagnosis of multiple sclerosis: a meta-synthesis of qualitative studies (2022)
Journal Article

Purpose: This meta-synthesis aimed to synthesise qualitative evidence on experiences of people with Multiple Sclerosis (MS) in receiving a diagnosis, to derive a conceptual understanding of adjustment to MS diagnosis. Methods: Five electronic databas... Read More about Experiences of receiving a diagnosis of multiple sclerosis: a meta-synthesis of qualitative studies.

Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England (2021)
Journal Article

Background: Contradicting assumptions have been made about the effectiveness of SARS-CoV-2 vaccines in patients with multiple sclerosis (MS) receiving immunomodulatory disease-modifying therapies (DMTs) based on the quantification of humoral and cell... Read More about Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England.

Recovery From COVID-19 in Multiple Sclerosis: A Prospective and Longitudinal Cohort Study of the United Kingdom Multiple Sclerosis Register (2021)
Journal Article

Background and Objectives: To understand the course of recovery from coronavirus disease 2019 (COVID-19) among patients with multiple sclerosis (MS) and to determine its predictors, including patients' pre–COVID-19 physical and mental health status.... Read More about Recovery From COVID-19 in Multiple Sclerosis: A Prospective and Longitudinal Cohort Study of the United Kingdom Multiple Sclerosis Register.

COVID-19 Vaccine Response in People with Multiple Sclerosis (2021)
Journal Article

Objective: The purpose of this study was to investigate the effect of disease modifying therapies on immune response to severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) vaccines in people with multiple sclerosis (MS). Methods: Four hundre... Read More about COVID-19 Vaccine Response in People with Multiple Sclerosis.

Memory rehabilitation for people with multiple sclerosis (2021)
Journal Article

Background Problems with cognition, particularly memory, are common in people with multiple sclerosis (MS) and can affect their ability to complete daily activities and can negatively affect quality of life. Over the last few years, there has been c... Read More about Memory rehabilitation for people with multiple sclerosis.

COVID-19 in Multiple Sclerosis: Clinically reported outcomes from the UK Multiple Sclerosis Register (2021)
Journal Article

Background: In March 2020, the United Kingdom Multiple Sclerosis Register (UKMSR) established an electronic case return form, designed collaboratively by MS neurologists, to record data about COVID-19 infections in people with MS (pwMS). Objectives:... Read More about COVID-19 in Multiple Sclerosis: Clinically reported outcomes from the UK Multiple Sclerosis Register.

Mild traumatic brain injury impairs the coordination of intrinsic and motor-related neural dynamics (2021)
Journal Article

Mild traumatic brain injury (mTBI) poses a considerable burden on healthcare systems. Whilst most patients recover quickly, a significant number suffer from sequelae that are not accompanied by measurable structural damage. Understanding the neural u... Read More about Mild traumatic brain injury impairs the coordination of intrinsic and motor-related neural dynamics.

Acceptance-based telephone support around the time of transition to secondary progressive multiple sclerosis: A feasibility randomised controlled trial (2021)
Journal Article

Introduction Transitioning to secondary progressive multiple sclerosis (SPMS) is a difficult time for people, fraught with psychological uncertainty and an increase in physical disability. In parallel, healthcare appointments become less frequent, m... Read More about Acceptance-based telephone support around the time of transition to secondary progressive multiple sclerosis: A feasibility randomised controlled trial.